The safety and efficacy of tocilizumab have been demonstrated in RA patients who have inadequate responses to MTX/DMARDs (MTX/DMARD-IR) or tumor necrosis factor-α inhibitor (TNFi) agents (TNFi-IR) [5]. The gene discussed is TNF; the disease is rheumatoid arthritis.